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Abstract
Background—The Vaccines for Children (VFC) program provides vaccines at no cost to 
children who are Medicaid-eligible, uninsured, American Indian or Alaska Native (AI/AN), or 
underinsured and vaccinated at Federally Qualified Health Centers or Rural Health Clinics. The 
objective of this study was to compare influenza vaccination coverage of VFC-entitled to privately 
insured children in the United States, nationally, by state, and by selected socio-demographic 
variables.
Methods—Data from the National Immunization Survey-Flu (NIS-Flu) surveys were analyzed 
for the 2011–2012 and 2012–2013 influenza seasons for households with children 6 months–17 
years. VFC-entitlement and private insurance status were defined based upon questions asked of 
the parent during the telephone interview. Influenza vaccination coverage estimates of children 
VFC-entitled versus privately insured were compared by t-tests, both nationally and within state, 
and within selected socio-demographic variables.
Results—For both seasons studied, influenza coverage for VFC-entitled children did not 
significantly differ from coverage for privately insured children (2011–2012: 52.0% ± 1.9% versus 
50.7% ± 1.2%; 2012–2013: 56.0% ± 1.6% versus 57.2% ± 1.2%). Among VFC-entitled children, 
uninsured children had lower coverage (2011–2012: 38.9% ± 4.7%; 2012–2013: 44.8% ± 3.5%) 
than Medicaid-eligible (2011–2012: 55.2% ± 2.1%; 2012–2013: 58.6% ± 1.9%) and AI/AN 
children (2011–2012: 54.4% ± 11.3%; 2012–2013: 54.6% ± 7.0%). Significant differences in 
vaccination coverage among VFC-entitled and privately insured children were observed within 
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some subgroups of race/ethnicity, income, age, region, and living in a metropolitan statistical area 
principle city.
Conclusions—Although finding few differences in influenza vaccination coverage among VFC-
entitled versus privately insured children was encouraging, nearly half of all children were not 
vaccinated for influenza and coverage was particularly low among uninsured children. Additional 
public health interventions are needed to ensure that more children are vaccinated such as a strong 
recommendation from health care providers, utilization of immunization information systems, 
provider reminders, standing orders, and community-based interventions such as educational 
activities and expanded access to vaccination services.
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1. Introduction
Seasonal influenza vaccination coverage among children 6 months–17 years has been 
increasing, from 43.7% in the 2009–2010 influenza season to 56.6% in the 2012–2013 
season [1–4]. Despite these increases, influenza vaccination coverage among children is still 
below the Healthy People 2020 (HP2020) revised target of 70% [5,6]. The Vaccines for 
Children (VFC) program has reduced racial/ethnic disparities in childhood vaccination 
coverage, improved vaccination rates among children, and fostered discontinuance of 
referring children to health department clinics by allowing children to be vaccinated in their 
medical home [7–9]. The VFC program was created by the Omnibus Budget Reconciliation 
Act of 1993 and first implemented in 1994, and is a federal entitlement program that 
provides vaccines at no cost to children who might not otherwise be vaccinated because of 
inability to pay [10,11]. Children ≤18 years are entitled to receive VFC vaccines if they are 
Medicaid-eligible, uninsured, American Indian or Alaska Native (AI/AN), or underinsured 
and vaccinated at Federally Qualified Health Centers (FQHC) or Rural Health Clinics 
(RHC) [11]. Studies of the association between insurance status and vaccination coverage 
among children for recommended vaccines other than influenza have shown that children 
with health insurance have higher vaccination coverage than uninsured children [12–18].
Differences in influenza vaccination coverage between VFC-entitled and privately insured 
children 6 months–17 years have not been evaluated with a national sample, nor have such 
differences in coverage been evaluated among socio-demographic subgroups of children. 
Identifying and quantifying any differences in childhood influenza vaccination coverage by 
insurance status could help guide public health action to increase influenza vaccination 
coverage for all children. This study was undertaken to compare influenza vaccination 
coverage of VFC-entitled versus privately insured children 6 months–17 years in the United 
States, nationally and by state, and to assess for any difference within select socio-
demographic subgroups.
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2. Methods
2.1. Survey description
We analyzed data from the National Immunization Survey-Flu (NIS-Flu) surveys for two 
influenza seasons: 2011–2012 and 2012–2013 [1–3]. The NIS-Flu survey is an ongoing, 
national list-assisted random-digit-dial survey of households with either landline telephone 
or cellular telephone numbers, and has a target population of non-institutionalized children 6 
months–17 years [1]. The survey includes three components: the NIS-Child for children 19–
35 months, the NIS-Teen for children 13–17 years, and a short child influenza module for 
children 6–18 months and 3–12 years [1,19,20]. The Council of American Survey and 
Research Organizations (CASRO) response rates for the 2011–2012 and 2012–2013 
influenza seasons ranged from 51.8% to 63.2% for the landline sample and 18.1% to 30.9% 
for the cellular telephone sample [21]. Data on child, maternal, and household socio-
demographic characteristics were collected during the telephone interviews.
2.2. VFC-entitled and private insurance group definitions
Data from the NIS-Flu surveys were used to evaluate whether the children were (i) on 
Medicaid, (ii) not covered by health insurance (uninsured), (iii) AI/AN, or (iv) privately 
insured. These evaluations were based upon insurance questions asked of the parent during 
the telephone interview. While the NIS-Child and NIS-Teen components of the NIS-Flu had 
a long series of questions to determine insurance status of the child, there were only two 
insurance questions included on the influenza module for children 6–18 months and 3–12 
years. The two questions were as follows: “Does [child] have any kind of health care 
coverage, including health insurance, prepaid plans such as Health Maintenance 
Organizations, or government plans such as Medicaid?” and “Is that coverage Medicaid, the 
State Children’s Health Insurance Program, or some other type of insurance?” Precise VFC-
entitlement status could not be determined because of the inability to identify the 
underinsured and vaccinated at FQHC/RHC group with the NIS-Flu survey questions. Thus, 
for this study, the VFC-entitled group consisted of children who were reported as uninsured, 
Medicaid-eligible, or AI/AN, categories which are not mutually exclusive. The privately 
insured group consisted of children reported as having private health insurance.
2.3. Influenza vaccination coverage assessment
Influenza vaccination status was assessed by asking the parent if the survey-selected 
child(ren) in the household had received an influenza vaccination since July 1 and, if so, in 
which month and year. The parental responses about whether a child had received influenza 
vaccine were not validated with medical records. For the 2011–2012 season, interview data 
collected during September 2011 through June 2012 were included in the analyses, and 
children reported to have received influenza vaccination July 2011 through May 2012 were 
considered vaccinated. For the 2012–2013 season, interview data collected during October 
2012 through June 2013 were included in the analyses, and children reported to have 
received influenza vaccination July 2012 through May 2013 were considered vaccinated. For 
children who were reported to have been vaccinated but had a missing month and year of 
vaccination (6.1% for the 2011–2012 season and 6.0% for the 2012–2013 season), month 
and year of vaccination was imputed from donor pools matched for week of interview, age 
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group, state of residence, and race/ethnicity [2,3]. Estimation of influenza vaccination 
coverage was based on the Kaplan–Meier survival analysis procedure that has been used to 
calculate season-specific estimates starting with the 2009–2010 influenza season [1,3,22,23]. 
Influenza vaccination coverage estimates were calculated by private health insurance and 
VFC-entitlement status at the national level. Influenza vaccination coverage by private 
health insurance and VFC-entitlement status was also calculated by state and within select 
socio-demographic sub-groups.
2.4. Statistical methods
Comparisons of influenza vaccination coverage estimates between VFC-entitled and 
privately insured children and between the 2011–2012 and 2012–2013 seasons were 
performed with t-tests assuming large degrees of freedom. All analyses were weighted to the 
United States population of non-institutionalized children 6 months–17 years. The weights 
used to calculate the routine parental-reported influenza vaccination coverage estimates for 
children that are published on CDC’s FluVaxView website could not be used for this study 
[24] because, for the NIS-Child and NIS-Teen components of the NIS-Flu, the insurance 
questions are asked only after the parent grants permission to contact the child’s vaccination 
provider to obtain vaccination records; insurance status is therefore missing for children 
whose parents did not grant permission for the NIS to contact their providers. Thus, a new 
set of weights was derived so that the sample of children with insurance information is 
representative of the population of non-institutionalized children 6 months–17 years in the 
United States. To quantify the possible extent of differences due to the reweighting, we 
compared the reweighted estimates for the subset of data analyzed for this study to the 
published final estimates that used all the data for both seasons studied. We found that for 
the 2011–2012 season, the differences between this study estimates and the published final 
estimates ranged from −1.6% to 0.5%. Similarly, for the 2012–2013 season, the differences 
ranged from −0.2% to 1.3%.
The analyses for this study included 83,411 children for the 2011–2012 season and 87,661 
children for the 2012–2013 season. All estimates, along with 95% confidence intervals 
(CIs), were calculated using SAS (SAS Institute, Inc., Cary, NC, version 9.3) and SUDAAN 
(Research Triangle Institute, Research Triangle Park, NC, version 10.01) to account for the 
complex survey design. All tests were two-sided and all comparisons noted as differences 
were statistically significant at alpha equal to 0.05 while comparisons noted as similar or the 
same were not statistically different at the p < 0.05 level.
2.5. Ethical approval
Institutional Review Board (IRB) approval for conducting the NIS-Flu was obtained through 
the National Center for Health Statistics Research Ethics Review Board and through the IRB 
of NORC at the University of Chicago.
3. Results
Nationally, 34.2% of children 6 months–17 years old were VFC-entitled during the 2011–
2012 season based on the proxy variable that excluded underinsured and vaccinated at 
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FQHC/RHC children, and 65.8% had private insurance (Table 1). In this season, 26.4% were 
enrolled in Medicaid, 6.6% were uninsured, and 2.2% were AI/AN. In the 2012–2013 
season, 37.0% of children were considered VFC-entitled with 28.6% enrolled in Medicaid, 
6.8% uninsured, and 3.1% AI/AN; 63.0% of children were privately insured. The 
distribution of socio-demographic characteristics of the sample surveyed is included in Table 
1.
Influenza vaccination coverage was higher in the 2012–2013 season compared to the 2011–
2012 season for both VFC-entitled (56.0% versus 52.0%) and privately insured children 
(57.2% versus 50.7%; Table 1). This increase occurred in all subgroups of VFC-entitlement 
studied except the AI/AN children in which coverage remained similar. Influenza 
vaccination coverage by the socio-demographic characteristics of the sample is included in 
Table 1.
Nationally, VFC-entitled children had similar influenza vaccination coverage compared to 
privately insured children in both influenza seasons studied, with coverage being 52.0% 
versus 50.7%, respectively, in the 2011–2012 season and 56.0% versus 57.2%, respectively, 
in the 2012–2013 season (Fig. 1). Within the VFC-entitled group of children, uninsured 
children had lower influenza vaccination coverage than Medicaid insured children in both 
seasons studied, with coverage being 38.9% versus 55.2%, respectively, in the 2011–2012 
season and 44.8% versus 58.6%, respectively, in the 2012–2013 season (Fig. 1).
By state, influenza vaccination coverage varied widely among VFC-entitled and privately 
insured children during both seasons (Table 2). During the 2011–2012 season, coverage 
among VFC-entitled children ranged from 34.2% in Arizona to 74.9% in Rhode Island, and 
coverage among privately insured children ranged from 34.7% in Alaska to 73.9% in Rhode 
Island. During the 2012–2013 season, coverage among VFC-entitled children ranged from 
40.3% in Missouri to 87.1% in Rhode Island, and coverage among privately insured children 
ranged from 41.6% in Montana to 81.4% in Rhode Island. Coverage among VFC-entitled 
children exceeded 70% in three states and among privately insured children in one state 
during the 2011–2012 season. Coverage among VFC-entitled children exceeded 70% in 
eight states and among privately insured children in four states during the 2012–2013 
season. In only nine states were there differences in coverage between VFC-entitled and 
privately insured children during the 2011–2012 season, and in two states during the 2012–
2013 season. During the 2011–2012 season, three states had lower coverage among VFC-
entitled children and six states had lower coverage among privately insured children. During 
the 2012–2013 season, one state had lower coverage among VFC-entitled children and one 
state had lower coverage among privately insured children. Comparing influenza vaccination 
coverage between seasons, VFC-entitled children had higher coverage in seven states and 
privately insured children had higher coverage in 16 states in the 2012–2013 season than in 
the 2011–2012 season.
In the 2011–2012 season, influenza vaccination coverage was similar among VFC-entitled 
and privately insured children for most socio-demographic groups studied (Table 3). For 
non-Hispanic white only children, coverage was higher among privately insured compared 
to VFC-entitled children. For four of the socio-demographic groups (age 13–17 years, MSA 
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principle city, Northeast, and Midwest), coverage was higher among VFC-entitled compared 
to privately insured children.
Again, for the 2012–2013 season, influenza vaccination coverage was similar among VFC-
entitled and privately insured children for most socio-demographic groups studied, but a 
different pattern was evident (Table 3). For six of the socio-demographic groups (age 6–23 
months, age 2–4 years, male, non-Hispanic white, non-Hispanic other/multiple race, and 
above poverty ≥$75,000), coverage was higher among privately insured compared to VFC-
entitled children. Coverage was not higher among the VFC-entitled children for any of the 
socio-demographic groups in 2012–2013 season.
4. Discussion
The findings of this study indicate that in both influenza seasons studied, VFC-entitled 
children had similar influenza vaccination coverage to privately insured children overall, and 
that within the VFC-entitled group uninsured children had influenza vaccination coverage 
that was at least 10 percentage points lower than the other two VFC-entitled groups of 
Medicaid and AI/AN children. Two studies have shown that vaccination coverage of other 
routinely administered vaccines among children 13–17 years was lower for VFC-entitled 
children compared to privately insured children [12,16]. Another study of children 19–35 
months showed differences in vaccination coverage based on insurance status [13]. A similar 
study showed that vaccination coverage for diphtheria–tetanus–aceullar pertussis, polio, 
measles–mumps–rubella, Haemophilus influenza type b, varicella, heptavalent 
pneumococcal conjugate (PCV7), and influenza vaccination was lower among VFC-entitled 
children than for privately insured children [15]. One additional study had shown that, 
compared to those who were fully insured, children who were underinsured and received 
vaccinations at a health department clinic had significantly lower vaccination coverage for 
the varicella and PCV7 vaccines [17]. In our study we could not assess the underinsured 
group of VFC-eligible children.
As in previous reports of childhood influenza vaccination coverage for the United States, we 
found large variability in influenza vaccination coverage between states. While several states 
achieved or surpassed the HP2020 target of 70% coverage, coverage remains low in many 
states. This variability was observed in both VFC-entitled and privately insured children. It 
is unknown to us why states vary widely in child influenza vaccination coverage, something 
that has been seen in the United States since the vaccine was first recommended for all 
children. The factors likely include varying degrees of programmatic and provider 
implementation of influenza recommendations, varying parental awareness, attitudes, and 
access to influenza vaccination services for their children, and other factors. Further study is 
needed to understand the variability in influenza vaccination coverage between states.
The findings of this study suggest that overall the influenza vaccination coverage among 
VFC-entitled children is similar to coverage among children who are privately insured; 
however, efforts are still needed to achieve the HP2020 revised target of 70% coverage in 
children 6 months–17 years. A striking difference was observed in the uninsured group 
which had the lowest coverage among the groups compared. These children are eligible for 
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the Vaccines for Children program but may not be aware of the program and may not have a 
medical home. With the implementation of the Affordable Care Act (ACA), it is expected 
that fewer children will be uninsured. The ACA helps make health insurance more available 
in three primary ways: (1) sets up a Health Insurance Marketplace where consumers may go 
to compare available insurance plans and enroll in the one they choose, (2) promotes the 
expansion of Medicaid programs in the states, and (3) reforms insurance market rules (e.g., 
eliminates denial of coverage for pre-existing conditions)1.
4.1. Strengths and limitations
The findings of this study are subject to several limitations. First, influenza vaccination 
status was based on parental report, not validated with medical records, and, thus, is subject 
to recall bias. A validity study has shown that parental report (for children) overestimates 
influenza vaccination coverage and may be more accurate for children who are privately or 
publicly insured as compared to parent report for uninsured children [25]. Second, NIS-Flu 
is a telephone survey that excludes households with no telephone service. Non-coverage and 
non-response bias may remain even after weighting adjustments. Third, we assessed 
influenza vaccination coverage with at least one dose of vaccination, but children younger 
than nine years often need two doses to be fully protected against influenza disease [26]. 
Fourth, our measure of VFC-entitlement included only three of the four VFC-entitlement 
criteria (Medicaid-eligible, uninsured, and AI/AN), as information was not available to 
identify underinsured children (likely less than 1%) [11,14] which would lead to a slight 
underestimation of the percentage of children who are eligible for the VFC program. Lastly, 
in the NIS-Flu VFC and insurance status for children 6–18 months and 3–12 years (62.5% 
of the study sample in 2011–2012, 62.6% in 2012–2013) were based upon parental report to 
a smaller set of questions than what was used for children 19–35 months (NIS-Child) and 
13–17 years (NIS-Teen) and, thus, may be subject to misclassification error. To quantify the 
possible extent of this error, we compared the NIS-Flu insurance variables to unpublished 
VFC administrative data. The 2013 VFC administrative data was collected using the child 
age groups <1 year, 1–2 years, 3–6 years, and 7–18 years. For these age groups, respectively, 
and based on the administrative data, 50.2%, 43.6%, 42.6%, and 32.1% of children in the 
United States were Medicaid insured in 2013 and 9.2%, 9.2%, 9.2%, and 9.1% were 
uninsured. An analysis of the NIS-Flu data for the 2012–2013 season by these same age 
groups (except 6–11 months instead of <1 year) indicated that 32.0%, 38.6%, 28.5%, and 
26.9% were Medicaid insured and 5.9%, 4.8%, 6.3% and 7.3% were uninsured. Thus the 
differences between the NIS-Flu and the administrative data were: 18.2%, 5.0%, 14.1%, and 
5.2% for Medicaid and 3.3%, 4.4%, 2.9%, and 1.8% for uninsured. This indicates that the 
largest amount of underestimation by the NIS-Flu insurance proxy variables occurred for 
Medicaid insured children <1 year (by 18 percentage points) and 3–6 years (by 14 
percentage points), and there was a 5 percentage point or less underestimation for the other 
age groups for Medicaid and for all age groups for uninsured children based on the NIS-Flu 
as compared to administrative data. This misclassification of Medicaid status is expected to 
dilute observed differences in vaccination coverage between VFC-entitled and privately 
1https://www.healthcare.gov/health-care-law-protections/#part8=undefined/part=8/.
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insured children, because some Medicaid-enrolled children will be misclassified as having 
private health insurance.
5. Conclusions
This study showed no national differences in influenza vaccination coverage by VFC-
entitlement status for the two influenza seasons studied. However, children who were 
uninsured had low vaccination coverage, and large state variability and some variability 
between demographic variables exists. Although the results are encouraging, influenza 
vaccination coverage was below the HP2020 target of 70% for almost every socio-
demographic group, indicating that improvement of coverage is needed to protect all 
children from influenza. Increased efforts are needed to implement evidence-based strategies 
proven to increase vaccination coverage such as a strong recommendation from health care 
providers, utilization of immunization information systems, provider reminders, standing 
orders, and community-based interventions such as educational activities and expanded 
access to vaccination services [27].
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Fig. 1. 
Influenza vaccination coverage among children 6 months–17 years by insurance status and 
Vaccines for Children (VFC) entitlement status, National Immunization Survey-Flu (NIS-
Flu), 2011–2012 and 2012–2013 influenza seasons. * AI/AN: Alaska Indian/Alaska Native. 
The VFC-entitled group does not include underinsured children. Uninsured children had 
lower influenza vaccination coverage than Medicaid insured children in both seasons (both p 
< 0.05); the uninsured children had lower coverage compared to the AI/AN group in both 
seasons (both p < 0.05), and the coverage of Medicaid insured children did not differ from 
coverage of AI/AN children.
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